Regenerative Medicine: A New Frontier for Therapeutic Intervention
Thursday 11th March 2010 at Riverside, Granta Park, Great Abington, Cambridge
sponsored and hosted by Pfizer, Regenerative Medicine Cambridge, UK
9.30 am Arrival, Registration and Coffee
Session 1: Chair: Dr. Wendy Alderton (CB1 Bio Ltd)
10.00 – 10.45 Dr Stephen Minger (Global Director R&D Cell Technologies, GE Healthcare,
UK) -Historical Perspective on Stem Cell Research
10.45 – 11.30 Professor Austin Smith (Wellcome Trust Centre for Stem Cell Research,
Cambridge University, UK) -Fundamental Biology of Stem Cells
11.30 – 12.15 Professor Peter Coffey (Institute of Ophthalmology, University College
London, UK) -Retinal pigmented epithelial cell therapy for the treatment of age related
macular degeneration
12.15 – 13.15 Lunch
Session 2: Chair: Dr Richard Davenport (Takeda Cambridge Ltd)
13.15 – 14.30 Dr Mark Bunnage (Head of Chemistry, Pfizer Regenerative Medicine, UK)
-Small molecule approaches for modulation of stem cell activity
14.30 – 15.15 Dr. Paul Kemp (CSO & Founder, Intercytex Ltd, UK)
-Perspective on the challenges of conducting clinical trials in regenerative medicines
15.15 – 15.45 Tea
Session 3 : Chair: Dr Ruth McKernan (Pfizer Regenerative Medicines, Cambridge)
15.45 – 16.30 Dr Eduardo Bravo (CEO of Cellerix, Spain)
-Ontaril: an autologous adipose tissue treatment
16.30 – 17.15 Dr Koenraad Blot (CMO of TiGenix, Belgium)
-The making of ChondroCelect: clinical and regulatory successes and challenges
17.15 Closing remarks and thanks – SMR Chairman
